Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study
Abstract
BACKGROUND
Dapagliflozin and empagliflozin are sodium-glucose cotransporter-2 inhibitors (SGLT2i) with equivalent Class IA guideline recommendations in heart failure with reduced ejection fraction (HFrEF).
OBJECTIVES
To compare the incidence of major adverse cardiovascular events (MACE) between dapagliflozin and empagliflozin in HFrEF patients treated in routine clinical practice.
METHODS
This prospective real-world cohort study enrolled 1231 consecutive HFrEF patients (left ventricular ejection fraction ≤40%) at Can Tho Central General Hospital, Vietnam (March 2023 to March 2026). Patients received dapagliflozin (n = 622) or empagliflozin (n = 609) as part of optimized guideline-directed medical therapy and the primary outcome was MACE.
RESULTS
MACE occurred in 64 patients (10.3%) receiving dapagliflozin and 111 patients (18.2%) receiving empagliflozin. Following propensity score matching and multivariable adjustment, dapagliflozin was associated with significantly lower odds of MACE (adjusted odds ratio [OR] 0.46; 95% confidence interval [CI] [0.30, 0.67]; p < 0.001). Hospitalization for heart failure was significantly lower with dapagliflozin (8.7% vs. 14.9%; adjusted OR 0.52; 95% CI [0.33, 0.80]; p = 0.003). Corrected all-cause mortality was 13/622 (2.1%) with dapagliflozin and 25/609 (4.1%) with empagliflozin (p = 0.048). Multivariable logistic regression identified four independent predictors of MACE: New York Heart Association functional class III-IV (adjusted OR…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,231 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.